Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Ayaneo says selling its Windows gaming handheld ‘is no longer sustainable’

March 24, 2026

Kymeta™ Unveils Kestrel™ u5: First-of-Its-Kind Satellite Terminal Delivering Unmatched Compact Performance

March 24, 2026

Cointelegraph Research and Trezor release report on the operational realities of self-custody

March 24, 2026

Food Lion Opens New Grocery Store in Simpsonville, S.C., on March 25

March 24, 2026

Vortex Weather Insurance Launches Direct Access to HailSafe Parametric Hail Insurance

March 24, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Asia-Pacific Cell and Gene Therapy Biomanufacturing Analysis and Forecast, 2022-2031 – A $8.60 Billion Projected Market by 2031
Press Release

Asia-Pacific Cell and Gene Therapy Biomanufacturing Analysis and Forecast, 2022-2031 – A $8.60 Billion Projected Market by 2031

By News RoomJanuary 30, 20243 Mins Read
Asia-Pacific Cell and Gene Therapy Biomanufacturing Analysis and Forecast, 2022-2031 – A .60 Billion Projected Market by 2031
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) — The “Asia-Pacific Cell and Gene Therapy Biomanufacturing Market – Analysis and Forecast, 2022-2031” report has been added to ResearchAndMarkets.com’s offering.

The global healthcare sector observes a momentous shift with the new research publication unveiling comprehensive insights into the Asia-Pacific Cell and Gene Therapy Biomanufacturing Market. This pivotal analysis anticipates a soaring Compound Annual Growth Rate (CAGR) of 17.88% from 2022 to 2031, marking a prolific increase from $1.96 billion to a staggering $8.60 billion.

Impetus for the Market Expansion

Factors propelling the market growth are cited to be the surge in authorized treatments and the burgeoning need for advanced biomanufacturing infrastructures capable of catering to an expanding array of target indications for cell and gene therapies.

Significant investments by governments, pharmaceutical giants, and academic institutions in the APAC region are setting the stage for novel breakthroughs in medical treatments, thereby fuelling the demand for sophisticated biomanufacturing solutions.

Market Segmentation

The report meticulously segments the market to furnish a granular analysis of the industry dynamics. The segmentation delves into:

  • Product Type, including Consumables, Equipment, and Software Solutions
  • End Users such as Life Science Companies, Contract Research Organizations (CROs), Contract Manufacturing Organizations (CMOs), and Cell Banks
  • Geographical distribution spanning China, Japan, India, South Korea, Australia/New Zealand, and the broader Rest-of-Asia-Pacific region

Strategic Analysis for Market Participants

For entities participating in the APAC market, the report presents an invaluable resource for formulating workflow and innovation strategies, as well as for guiding growth and marketing efforts to capture the emergent opportunities in cell and gene therapy biomanufacturing.

Industry Drivers and Challenges

Among the primary drivers underpinning the market’s promising outlook are:

  • The ongoing expansion in target indications requiring large-scale biomanufacturing capabilities.
  • The influx of new market entrants necessitating a robust infrastructure for biomanufacturing.
  • A robust clinical pipeline further demanding enhanced biomanufacturing infrastructure.

Conversely, the market must navigate through challenges such as the high initial setup costs associated with biomanufacturing facilities.

Competitive Landscape and Key Market Innovators

Comprehensive profiling of leading market contributors reveals the competitive strategic landscapes. This analysis highlights the key players’ innovative product launches, acquisitions, expansions, and strategic collaborations, offering a competitive benchmarking that elucidates the position of each market player.

Potential for Transformational Impact

Encompassing a period of rapid industrial change and projected growth, the findings within the report underscore the Asia-Pacific region’s critical role in the global biomanufacturing landscape.

With the market poised for exponential growth, stakeholders across the healthcare and biotechnology sectors are set to witness an era marked by groundbreaking advancements and strategic market shifts in cell and gene therapy biomanufacturing.

Key Attributes:

Report Attribute Details
No. of Pages 108
Forecast Period 2022 – 2031
Estimated Market Value (USD) in 2022 $1.96 Billion
Forecasted Market Value (USD) by 2031 $8.6 Billion
Compound Annual Growth Rate 17.8%
Regions Covered Asia Pacific

Key Market Segmentation:

Segmentation by Product Type

  • Consumables
  • Equipment
  • Software Solutions

Segmentation by End User

  • Life Science Companies
  • Contract Research Organizations (CROs)
  • Contract Manufacturing Organizations (CMOs)
  • Cell Banks

Segmentation by Country

  • China
  • Japan
  • India
  • South Korea
  • Australia/New Zealand
  • Rest-of-Asia-Pacific

For more information about this report visit https://www.researchandmarkets.com/r/oyqvry

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Asia-Pacific Cell and Gene Therapy Biomanufacturing Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Kymeta™ Unveils Kestrel™ u5: First-of-Its-Kind Satellite Terminal Delivering Unmatched Compact Performance

Cointelegraph Research and Trezor release report on the operational realities of self-custody

Food Lion Opens New Grocery Store in Simpsonville, S.C., on March 25

Vortex Weather Insurance Launches Direct Access to HailSafe Parametric Hail Insurance

Dieter’s Celebrates 50 Years of Craftsmanship, Innovation, and Quality in the Heavy-Duty Truck Industry

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Scientists and explorers unite at the Yacht Club de Monaco for ‘A Day of Exploration’

Reborn Coffee Celebrates Grand Opening of Shenzhen Flagship Location at Tencent Headquarters Campus, Marking Strategic Next Phase of China Expansion

Southern Glazer’s Wine & Spirits Deploys Corvus Robotics Drone Inventory System Nationwide

Editors Picks

Kymeta™ Unveils Kestrel™ u5: First-of-Its-Kind Satellite Terminal Delivering Unmatched Compact Performance

March 24, 2026

Cointelegraph Research and Trezor release report on the operational realities of self-custody

March 24, 2026

Food Lion Opens New Grocery Store in Simpsonville, S.C., on March 25

March 24, 2026

Vortex Weather Insurance Launches Direct Access to HailSafe Parametric Hail Insurance

March 24, 2026

Latest News

Dieter’s Celebrates 50 Years of Craftsmanship, Innovation, and Quality in the Heavy-Duty Truck Industry

March 24, 2026

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

March 24, 2026

‘We will go to court’: Chief pushes back after FSIN asked to repay $27.6M

March 24, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version